KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Profit After Tax (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Profit After Tax data on record, last reported at $273.6 million in Q4 2025.

  • For Q4 2025, Profit After Tax rose 90.32% year-over-year to $273.6 million; the TTM value through Dec 2025 reached $404.6 million, up 78.65%, while the annual FY2025 figure was $391.0 million, 72.66% up from the prior year.
  • Profit After Tax reached $273.6 million in Q4 2025 per ACAD's latest filing, up from $71.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $273.6 million in Q4 2025 and bottomed at -$113.1 million in Q1 2022.
  • Average Profit After Tax over 5 years is $9.3 million, with a median of -$6.7 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: plummeted 139.77% in 2023, then skyrocketed 2897.22% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$43.1 million in 2021, then increased by 3.18% to -$41.7 million in 2022, then surged by 209.76% to $45.8 million in 2023, then skyrocketed by 213.87% to $143.7 million in 2024, then surged by 90.32% to $273.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $273.6 million in Q4 2025, $71.8 million in Q3 2025, and $40.2 million in Q2 2025.